Van Keuren-Jensen Kendall R, Malenica Ivana, Courtright Amanda L, Ghaffari Layla T, Starr Alex P, Metpally Raghu P, Beecroft Taylor A, Carlson Elizabeth W J, Kiefer Jeffrey A, Pockros Paul J, Rakela Jorge
Neurogenomics, Translational Genomics Research Institute, Phoenix, AZ, USA.
Division of Gastroenterology/Hepatology, Scripps, La Jolla, CA, USA.
Liver Int. 2016 Mar;36(3):334-43. doi: 10.1111/liv.12919. Epub 2015 Sep 9.
BACKGROUND & AIMS: Accumulating evidence indicates that microRNAs play a role in a number of disease processes including the pathogenesis of liver fibrosis in hepatitis C infection. Our goal is to add to the accruing information regarding microRNA deregulation in liver fibrosis to increase our understanding of the underlying mechanisms of pathology and progression.
We used next generation sequencing to profile all detectable microRNAs in liver tissue and serum from patients with hepatitis C, stages F1-F4 of fibrosis.
We found altered expression of several microRNAs, in particular, miR-182, miR199a-5p, miR-200a-5p and miR-183 were found to be significantly upregulated in tissue from liver biopsies of hepatitis C patients with advanced fibrosis, stage F3 and F4, when compared with liver biopsies from patients with early fibrosis, stages F1 and F2. We also found miR-148-5p, miR-1260b, miR-122-3p and miR-378i among the microRNAs most significantly down-regulated from early to advanced fibrosis of the liver. We also sequenced the serum microRNAs; however, we were not able to detect significant changes in circulating microRNAs associated with fibrosis stage after adjusting for multiple tests.
Adding measurements of tissue microRNAs acquired during routine biopsies will continue to increase our knowledge of underlying mechanisms of fibrosis. Our goal is that these data, in combination with studies from other researchers and future long-term studies, could be used to enhance the staging accuracy of liver biopsies and expand the surveillance of patients at increased risk for cancer and progression to advanced fibrosis.
越来越多的证据表明,微小RNA在包括丙型肝炎感染所致肝纤维化发病机制在内的多种疾病过程中发挥作用。我们的目标是增加有关肝纤维化中微小RNA失调的累积信息,以加深我们对病理和进展潜在机制的理解。
我们使用新一代测序技术对丙型肝炎纤维化F1-F4期患者肝组织和血清中所有可检测的微小RNA进行分析。
我们发现几种微小RNA的表达发生了改变,特别是,与早期纤维化(F1和F2期)患者的肝活检组织相比,在晚期纤维化(F3和F4期)的丙型肝炎患者肝活检组织中,miR-182、miR199a-5p、miR-200a-5p和miR-183被发现显著上调。我们还发现,在肝脏从早期到晚期纤维化过程中,miR-148-5p、miR-1260b、miR-122-3p和miR-378i是下调最显著的微小RNA。我们也对血清微小RNA进行了测序;然而,在进行多次检验校正后,我们未能检测到与纤维化分期相关的循环微小RNA有显著变化。
增加在常规活检过程中获取的组织微小RNA测量值将继续增加我们对纤维化潜在机制的认识。我们的目标是,这些数据与其他研究人员的研究以及未来的长期研究相结合,可用于提高肝活检的分期准确性,并扩大对癌症风险增加和进展为晚期纤维化患者的监测。